Identifying and Managing Adverse Reactions to Lenvatinib and Pembrolizumab
Researchers have characterized common adverse reactions to combination lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma.
Researchers have characterized common adverse reactions to combination lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma.
A survey of US urologic oncologists suggests that reproductive organ-sparing and nerve-sparing radical cystectomy may be underused in women with bladder cancer.
Adding interferon alfa to treatment with temozolomide and radiotherapy prolongs survival in patients with newly diagnosed, high grade glioma, a phase 3 trial suggests.
US medical oncologists may lack understanding of biosimilars and have limited access to education about these products, a survey suggests.
Combination avelumab and axitinib has shown long-term activity in previously untreated patients with advanced renal cell carcinoma.
The COVID-19 pandemic has hindered the early diagnosis and treatment of cancer, and this may have set back cancer outcomes by almost a decade in Europe, a new report suggests.
In the absence of immunosuppression, systemic cancer therapies do not increase the risk of severe COVID-19 or cytokine storm, a study suggests.
Adjuvant atezolizumab can prevent recurrence and death, thereby reducing costs, in patients with early non-small cell lung cancer, a study suggests.
Patients with mHSPC who receive enzalutamide plus ADT are 4 times more likely to achieve undetectable PSA levels than patients who receive ADT alone, according to an analysis of data from the ARCHES trial.
Real-world data support first-line palbociclib plus an aromatase inhibitor as standard care for HR+, HER2- metastatic breast cancer, according to researchers.